{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T18:06:40Z","timestamp":1780682800927,"version":"3.54.1"},"reference-count":31,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: The optimal antiplatelet strategy after transcatheter aortic valve implantation (TAVI) in patients who do not require long-term oral anticoagulation remains debated. Randomized trial evidence supports single antiplatelet therapy (SAPT) over dual antiplatelet therapy (DAPT), yet real-world practice patterns and the magnitude of benefit in contemporary TAVI populations remain heterogeneous. Methods: We analyzed consecutive patients undergoing TAVI at a single tertiary center between April 2009 and April 2023 who were discharged on an antiplatelet regimen only. Patients on chronic oral anticoagulation were excluded. The exposure was defined by the discharge regimen (SAPT vs. DAPT), treated as a time-varying variable with person-time split at the documented date of any regimen change. The pre-specified efficacy endpoint was ischemic major adverse cardiovascular events (iMACE: death, stroke, or myocardial infarction); net adverse clinical events (NACEs) added major bleeding. The primary analysis was a time-varying Cox model adjusted for baseline variables. Sensitivity analyses included an intention-to-treat Cox model, a 6-month landmark Cox model, and an inverse-probability-of-treatment-weighted (IPTW) time-varying Cox model. Results: Of 662 eligible patients, 147 (22.2%) were discharged on SAPT and 515 (77.8%) on DAPT. Median follow-up was 34 months (IQR 14\u201352). During follow-up, 141 iMACE and 146 NACEs occurred. In the primary time-varying Cox model, the adjusted hazard ratio for DAPT versus SAPT was 1.28 (95% CI 0.81\u20132.04; p = 0.292) for iMACE and 0.71 (95% CI 0.44\u20131.14; p = 0.159) for NACE. None of the sensitivity models demonstrated a statistically significant difference between groups. Major bleeding was rare (six events; two SAPT, four DAPT). The 30-day landmark analysis showed no signal of an effect of regimen on late stroke (HR 1.12, 95% CI 0.39\u20133.12). Conclusions: In a contemporary real-world TAVI cohort, no statistically significant difference between SAPT and DAPT was observed for ischemic or net adverse clinical events. These findings demonstrate no ischemic disadvantage of SAPT compared with DAPT in real-world practice and are consistent with the randomized evidence base supporting SAPT as a reasonable default antiplatelet strategy after TAVI in patients without another antithrombotic indication. The bleeding endpoint was underpowered, and the expected bleeding advantage of SAPT could not be independently evaluated in this cohort.<\/jats:p>","DOI":"10.3390\/jcm15114381","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T17:18:16Z","timestamp":1780679896000},"page":"4381","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Single Versus Dual Antiplatelet Therapy After Transcatheter Aortic Valve Implantation in Patients Without Chronic Anticoagulation"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5163-5987","authenticated-orcid":false,"given":"Monirah A.","family":"Albabtain","sequence":"first","affiliation":[{"name":"Research Department, Prince Sultan Cardiac Center, Riyadh 12233, Saudi Arabia"},{"name":"Pharmacy Department, Prince Sultan Cardiac Center, Riyadh 12231, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Alrasheedi","sequence":"additional","affiliation":[{"name":"Pharmacy Department, King Fahad Specialist Hospital, Buraydah 52366, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1642-2149","authenticated-orcid":false,"given":"Razan M.","family":"Awan","sequence":"additional","affiliation":[{"name":"Pharmacy Department, King Fahad Armed Forces Hospital, Jeddah 23311, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7478-2533","authenticated-orcid":false,"given":"Maha","family":"Alharthi","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Prince Sultan Cardiac Center, Riyadh 12231, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid","family":"Alanazi","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Prince Sultan Cardiac Center, Riyadh 12231, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawaf","family":"Aldhubayti","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Prince Sultan Cardiac Center, Riyadh 12231, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0951-7287","authenticated-orcid":false,"given":"Amr A.","family":"Arafat","sequence":"additional","affiliation":[{"name":"Research Department, Prince Sultan Cardiac Center, Riyadh 12233, Saudi Arabia"},{"name":"Research & Innovation Institute, Ministry of Defense Health Services, Riyadh 12426, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa1814052","article-title":"Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients","volume":"380","author":"Mack","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa1816885","article-title":"Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients","volume":"380","author":"Popma","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e1126","DOI":"10.4244\/EIJ-E-21-00009","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"17","author":"Vahanian","year":"2022","journal-title":"EuroIntervention"},{"key":"ref_4","first-page":"e72\u2013227","article-title":"2020 ACC\/AHA Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijcard.2014.04.170","article-title":"SAT-TAVI (single antiplatelet therapy for TAVI) study: A pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation","volume":"174","author":"Stabile","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10557-021-07146-6","article-title":"Aspirin Versus Dual Antiplatelet Therapy in Patients Undergoing Trans-Catheter Aortic Valve Implantation, Updated Meta-Analysis","volume":"36","author":"Alkhalil","year":"2022","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_7","first-page":"12","article-title":"Single Versus Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting for Unprotected Left-Main Coronary Disease","volume":"23","author":"Daoulah","year":"2024","journal-title":"Crit. Pathw."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Awan, R., Albabtain, M.A., AlRasheedi, A., AlHarthi, M., Alanazi, Z., and Arafat, A.A. (2025). Personalized Antithrombotic Strategies in Patients with Atrial Fibrillation Following Transcatheter Aortic Valve Replacement. J. Pers. Med., 15.","DOI":"10.3390\/jpm15040149"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1056\/NEJMoa2017815","article-title":"Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation","volume":"383","author":"Brouwer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jcin.2017.04.014","article-title":"Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement with a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomized Clinical Trial","volume":"10","author":"Masson","year":"2017","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1093\/eurheartj\/ehac242","article-title":"Apixaban vs. standard of care after transcatheter aortic valve implantation: The ATLANTIS trial","volume":"43","author":"Collet","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement","volume":"382","author":"Dangas","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.amjcard.2018.04.006","article-title":"Meta-Analysis Comparing Single Versus Dual Antiplatelet Therapy Following Transcatheter Aortic Valve Implantation","volume":"122","author":"Maes","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.jacc.2020.08.049","article-title":"Structural Deterioration of Transcatheter Versus Surgical Aortic Valve Bioprostheses in the PARTNER-2 Trial","volume":"76","author":"Pibarot","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"61","author":"Altman","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"World-Medical-Association (2013). World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA, 310, 2191\u20132194.","DOI":"10.1001\/jama.2013.281053"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.jacc.2021.02.038","article-title":"Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research","volume":"77","author":"Piazza","year":"2021","journal-title":"JACC"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.gheart.2018.08.004","article-title":"Fourth Universal Definition of Myocardial Infarction (2018)","volume":"13","author":"Thygesen","year":"2018","journal-title":"Glob. Heart"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s43057-026-00196-2","article-title":"Statistical analysis guidelines for The Cardiothoracic Surgeon: A comprehensive framework for study design, analysis, and reporting","volume":"34","author":"Arafat","year":"2026","journal-title":"Cardiothorac. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Therneau, T.M., and Grambsch, P.M. (2000). Modeling Survival Data: Extending the Cox Model, Springer.","DOI":"10.1007\/978-1-4757-3294-8"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/CIRCOUTCOMES.110.957951","article-title":"Landmark Analysis at the 25-Year Landmark Point","volume":"4","author":"Dafni","year":"2011","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the Analysis of Survival Data in the Presence of Competing Risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity Analysis in Observational Research: Introducing the E-Value","volume":"167","author":"Ding","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s43057-025-00171-3","article-title":"Does preoperative antiplatelet therapy worsen outcomes in acute type A aortic dissection surgery? A meta-analytic review","volume":"33","author":"Santos","year":"2025","journal-title":"Cardiothorac. Surg."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s43057-025-00149-1","article-title":"Early dual antiplatelet therapy (DAPT) administration within 6 h post-coronary artery bypass grafting (CABG): An audit, pilot study, and follow-up analysis","volume":"33","author":"Chen","year":"2025","journal-title":"Cardiothorac. Surg."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"101719","DOI":"10.1016\/j.jacadv.2025.101719","article-title":"Post-Transcatheter Aortic Valve Replacement Antithrombotic Treatment in Nonindicated Patients","volume":"4","author":"Siami","year":"2025","journal-title":"JACC Adv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/j.jacc.2020.09.595","article-title":"STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement","volume":"76","author":"Carroll","year":"2020","journal-title":"JACC"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jacc.2017.04.053","article-title":"Temporal Trends in Transcatheter Aortic Valve Replacement in France","volume":"70","author":"Auffret","year":"2017","journal-title":"JACC"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s43057-022-00094-3","article-title":"Isolated surgical vs. transcatheter aortic valve replacement: A propensity score analysis","volume":"31","author":"Almedimigh","year":"2023","journal-title":"Cardiothorac. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal Structural Models and Causal Inference in Epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/11\/4381\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T17:52:27Z","timestamp":1780681947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/11\/4381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["jcm15114381"],"URL":"https:\/\/doi.org\/10.3390\/jcm15114381","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]}}}